TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis

Author:

Yan Dehong1ORCID,Wang Jinghui12,Sun Honghong3,Zamani Ali3,Zhang Honglin1,Chen Weihong4,Tang Aifa4,Ruan Qingguo1,Yang Xiaolu5,Chen Youhai H.3ORCID,Wan Xiaochun1

Affiliation:

1. Shenzhen Laboratory for Human Antibody Engineering, Center for Protein and Cell-based Drugs, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

2. College of Life Science and Technology, Jinan University, Guangzhou, China

3. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

4. Department of Hematology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China

5. Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Abstract

Myeloid-derived suppressor cells (MDSCs) are “polarized” myeloid cells that effectively promote tumorigenesis by inhibiting antitumor immunity. How myeloid cells acquire the protumoral properties during tumorigenesis is poorly understood. We report here that the polarity protein TIPE2 (tumor necrosis factor-α–induced protein 8-like 2) mediates the functional polarization of murine and human MDSCs by specifying their pro- and antitumoral properties. Tumor cells induced the expression of TIPE2 in Gr1+CD11b+ cells through reactive oxygen species (ROS). TIPE2 in turn increased the expression of protumoral mediators such as CCAAT/enhancer-binding protein-β while inhibiting the expression of antitumoral mediators. Consequently, tumor growth in TIPE2-deficient mice was significantly diminished, and TIPE2-deficient MDSCs markedly inhibited tumor growth upon adoptive transfer. Pharmaceutical blockade of ROS inhibited TIPE2 expression in MDSCs and reduced tumor growth in mice. These findings indicate that TIPE2 plays a key role in the functional polarization of MDSCs and represents a new therapeutic target for cancer immunotherapy.

Funder

National Natural Science Foundation of China

Science and Technology Project of Guangdong

Shenzhen Basic Science Research Project

Shenzhen Technology Innovation Project

Nanshan Pilot Team Project

Shenzhen Peacock Next-Generation Monoclonal Antibody Drug Research and Development Program

Fourth Talents Project of Guangdong Province

Special Funds for Major Science and Technology of Guangdong Province

Guangdong Provincial Research Award for Scholars

Shenzhen Laboratory of Fully Human Antibody Engineering

Shenzhen Special Funds for Industry of the Future

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3